First-time drug study for advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and you’re expected to live at least 3 months
- You have an advanced solid tumor that has grown despite, or doesn’t allow, standard treatments
- Your scans show at least one measurable tumor spot (per RECIST 1.1) during screening
- Your health and lab tests are in acceptable ranges (blood counts, liver, kidneys, heart rhythm, thyroid)
- You must not start other cancer treatments right before the first dose (typically no treatment in the prior 4 weeks)
- If you can become pregnant, you must use reliable birth control during the study and for 3 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1/2 trial tests MHB036C in people with advanced or metastatic solid cancers that have stopped responding to standard treatments (or no standard options exist). It is meant to see how the drug works and how safe it is in this group.
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
This Phase 1 trial studies ZG0895.HCl, a new experimental treatment, in people with advanced solid cancers. It’s mainly to check safety and how the body responds, and it may help by shrinking or controlling tumors if the drug works.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.